May 2021 | Targeted Therapies in Oncology

PSMA Theranostics Is Poised to Change Prostate Cancer Landscape

May 22, 2021

Clinical Articles

Although research focused on prostate-specific membrane antigen has been ongoing for almost 2 decades, the timing for the emergence of prostate-specific membrane antigen theranostics could not have been any better.

Experts in Ovarian Cancer Discuss Targeted Agent Combinations and Disparities in Care

May 20, 2021

The ovarian cancer treatment landscape, including the use of cytotoxic and targeted therapies, is continuously evolving for patients. Recent trials have evaluated PARP inhibitors, antiangiogenic agents, and other targeted therapies, and investigators are looking at strategies to individualize care for patients with ovarian cancer.

Ruxolitinib in GVHD Reveals Lower Risk of Relapse, Longer Duration of Response

May 20, 2021

Clinical Articles

Findings from the phase 3 REACH2 trial demonstrated a lower risk of relapse and longer median duration of response with ruxolitinib versus best available therapy in patients with steroid-refractory acute graft-versus-host disease.

Urothelial Cancer Guidelines Are Updated to Include Immune Checkpoint Inhibitors

May 17, 2021

Clinical Articles

Immunotherapies are now accepted treatments in the maintenance and second-line settings for patients with metastatic urothelial cancer and in the setting of superficial UC–carcinoma in situ with prior intravesical therapy, according to updated NCCN guidelines

Liso-Cel for Patients With R/R LBCL Shows Promising Results in Real-World Settings

May 15, 2021

Clinical Articles

Patients with relapsed or refractory aggressive large B-cell lymphoma showed promising results from the administration of lisocabtagene maraleucel in both inpatient and outpatient non–university hospital settings.

Narsoplimab Exceeds Expectations Across High-Risk HSCT-TMA Subtype

May 14, 2021

Clinical Articles

Administered narsoplimab in patients with high-risk hematopoietic stem cell transplant– associated thrombotic microangiopathy resulted in a response rate of 61% among all patients treated with the monoclonal antibody

PSMA-Directed Therapies and Diagnostics Expand Their Scope in Prostate Cancer

May 14, 2021

Clinical Articles

With the emergence of therapies that target PSMA, a cell surface transmembrane protein that is overexpressed in most prostate cancer cells, particularly in castration-resistant disease, the ability to detect and treat the disease has been transformed.